Crestor approved for paediatric and prophylactic use

Crestor (rosuvastatin) has been approved for two additional indications: heterozygous familial hypercholesterolaemia in children aged 10–17 years and primary prevention of major cardiovascular events in high-risk adults.

Children prescribed Crestor must be at least Tanner Stage II (boys) or 1-year post-menarche (girls).

The prevention indication is based on a post-hoc analysis of the JUPITER study, which revealed that rosuvastatin 20mg daily significantly reduced the combined risk of cardiovascular death, stroke and myocardial infarction in high-risk patients. This trial showed a small increase in the risk of diabetes in patients taking rosuvastatin, compared with those taking placebo.

View Crestor drug record

Further information: AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more